PT of her surgical sample revealed somatic mutations in TP53 and a hemizygous loss of NF2, yielding four possible therapies, including an mTOR inhibitor, everolimus, approved in combination with anti‐hormonal therapy for metastatic BC. This evidence concerns the gene NF2 and breast cancer.